Yidao Biotechnology is a technology company.
Yidao Biotechnology has raised $87.0M across 2 funding rounds.
Yidao Biotechnology has raised $87.0M in total across 2 funding rounds.
Yidao Biotechnology has raised $87.0M in total across 2 funding rounds.
Yidao Biotechnology's investors include Qiming Venture Partners.
Yidao Biotechnology (Suzhou) Co., Ltd. is a Chinese biotechnology company specializing in the research and development of vaccines and biomedical products. Its portfolio includes recombinant protein, viral vector, peptide-polysaccharide conjugate, and mRNA vaccines aimed at providing high-quality, cost-effective immunization solutions. The company primarily serves healthcare providers and patients by addressing infectious diseases and certain cancers through prophylactic and therapeutic vaccines. Yidao has demonstrated growth momentum through advancing multiple vaccine candidates into clinical trials, including a recombinant zoster vaccine currently in Phase 3 and therapeutic vaccines targeting uterine cervical cancer[1][2][3][4].
Founded in 2017 and headquartered in Jiangsu Sheng, China, Yidao Biotechnology was established to innovate in vaccine technology and biomedical research. While specific founder details are not publicly highlighted, the company emerged amid rising global demand for advanced vaccine platforms, including mRNA technology. Early traction is evidenced by its accumulation of 29 patents and progression of several vaccine candidates into clinical development phases, marking pivotal milestones in its growth trajectory[1][4][6].
Yidao Biotechnology rides the global trend of accelerating vaccine innovation, particularly in mRNA and recombinant technologies, which have gained prominence post-COVID-19. The timing aligns with increasing demand for novel vaccines against infectious diseases and cancers, supported by favorable market forces such as government funding and heightened public health awareness. Yidao’s work contributes to expanding vaccine options in China and globally, influencing the biotech ecosystem by advancing next-generation vaccine platforms and addressing unmet medical needs[3][4].
Looking ahead, Yidao Biotechnology is poised to leverage its diverse vaccine technologies and clinical progress to expand its market presence. Trends shaping its journey include continued growth in mRNA vaccine applications, increasing demand for therapeutic cancer vaccines, and global emphasis on infectious disease prevention. As it moves vaccines through late-stage trials and potentially to market approval, Yidao’s influence in the biotech and public health sectors is likely to grow, reinforcing its role as an innovator in affordable, effective vaccine solutions[2][4]. This trajectory ties back to its founding mission to develop impactful biomedical products that address critical health challenges.
Yidao Biotechnology has raised $87.0M across 2 funding rounds. Most recently, it raised $25.0M Series D in May 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2024 | $25.0M Series D | Qiming Venture Partners | |
| May 1, 2021 | $62.0M Series C | Qiming Venture Partners |